Lithium Treatment in Patients With Huntington's Disease and Suicidal Behavior

Publisher： John Wiley & Sons Inc

E-ISSN： 1531-8257|30|10|1438-1438

ISSN： 0885-3185

Source： MOVEMENT DISORDERS, Vol.30, Iss.10, 2015-09, pp. : 1438-1438

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Reply: Suicidality in Huntington's Disease: Distinguishing lithium from other psychotropic medications

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 10, 2015-09 ,pp. : 1438-1439

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pridopidine in the pharmacological treatment of Huntington’s disease

By Michl Martin   Schnopfhagen Katharina   Bonelli Raphael M  

Clinical Investigation, Vol. 3, Iss. 7, 2013-07 ,pp. : 691-699

Future Science

Access to resources Recommend Favorite

Cannabinoids: Novel Medicines for the Treatment of Huntington's Disease

By  

Recent Patents on CNS Drug Discovery, Vol. 7, Iss. 1, 2012-04 ,pp. : 41-48

Bentham Science Publishers

Access to resources Recommend Favorite

Potential trade‐offs in treatment of premanifest Huntington's disease

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 10, 2015-09 ,pp. : 1319-1323

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomized, placebo‐controlled trial of AFQ056 for the treatment of chorea in Huntington's disease

By  

MOVEMENT DISORDERS, Vol. 30, Iss. 3, 2015-03 ,pp. : 427-431

John Wiley & Sons Inc

Access to resources Recommend Favorite